Terms: = Skin cancer AND CLTC, CLTCL2, 1213, ENSG00000141367, Q00610 AND Treatment
19 results:
1. Long-term outcome after surgical resection of non-high-risk gastrointestinal stromal tumours without adjuvant therapy.
Berndsen M; Renberg S; Hølmebakk T; Hancke E; Puls F; Karlsson F; Stoldt S; Bjerkehagen B; Haglund de Flon F; Muth A; Papakonstantinou A; Boye K; Lindskog S
Br J Surg; 2023 Nov; 110(12):1857-1862. PubMed ID: 37758514
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma.
Wu MP; Reinshagen KL; Cunnane MB; Shalhout SZ; Kaufman HL; Miller D; Emerick KS
Laryngoscope; 2022 Jun; 132(6):1213-1218. PubMed ID: 34797598
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental treatments.
Coquerelle S; Darlington M; Michel M; Durand M; Borget I; Baffert S; Marino P; Perrier L; Durand-Zaleski I;
Value Health; 2020 Jul; 23(7):898-906. PubMed ID: 32762992
[TBL] [Abstract] [Full Text] [Related]
4. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
[TBL] [Abstract] [Full Text] [Related]
5. Primary excision margins, sentinel lymph node biopsy, and completion lymph node dissection in cutaneous melanoma: a clinical practice guideline.
Wright FC; Souter LH; Kellett S; Easson A; Murray C; Toye J; McCready D; Nessim C; Ghazarian D; Hong NJL; Johnson S; Goldstein DP; Petrella T;
Curr Oncol; 2019 Aug; 26(4):e541-e550. PubMed ID: 31548823
[TBL] [Abstract] [Full Text] [Related]
6. A nomogram to identify high-risk melanoma patients with a negative sentinel lymph node biopsy.
Bertolli E; de Macedo MP; Calsavara VF; Pinto CAL; Duprat Neto JP
J Am Acad Dermatol; 2019 Mar; 80(3):722-726. PubMed ID: 30395920
[TBL] [Abstract] [Full Text] [Related]
7. Perioperative BRAF inhibitors in locally advanced stage III melanoma.
Zippel D; Markel G; Shapira-Frommer R; Ben-Betzalel G; Goitein D; Ben-Ami E; Nissan A; Schachter J; Schneebaum S
J Surg Oncol; 2017 Dec; 116(7):856-861. PubMed ID: 28650570
[TBL] [Abstract] [Full Text] [Related]
8. Prospective pilot study of CT-guided microwave ablation in the treatment of osteoid osteomas.
Prud'homme C; Nueffer JP; Runge M; Dubut J; Kastler B; Aubry S
Skeletal Radiol; 2017 Mar; 46(3):315-323. PubMed ID: 28028574
[TBL] [Abstract] [Full Text] [Related]
9. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological spectrum of a series of Merkel cell carcinomas diagnosed at a tertiary cancer referral center in India, with current concepts.
Rekhi B; Kane SV; Jambhekar NA
Ann Diagn Pathol; 2015 Oct; 19(5):341-6. PubMed ID: 26254510
[TBL] [Abstract] [Full Text] [Related]
11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract] [Full Text] [Related]
12. Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR.
How-Kit A; Lebbé C; Bousard A; Daunay A; Mazaleyrat N; Daviaud C; Mourah S; Tost J
Anal Bioanal Chem; 2014 Sep; 406(22):5513-20. PubMed ID: 24969466
[TBL] [Abstract] [Full Text] [Related]
13. Do breast cups improve breast cancer dosimetry? A comparative study for patients with large or pendulous breasts.
Arenas M; Hernández V; Farrús B; Müller K; Gascón M; Pardo A; Berenguer R; Sabater S
Acta Oncol; 2014 Jun; 53(6):795-801. PubMed ID: 24655017
[TBL] [Abstract] [Full Text] [Related]
14. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
Karayannopoulou G; Euvrard S; Kanitakis J
Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
[TBL] [Abstract] [Full Text] [Related]
15. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
[TBL] [Abstract] [Full Text] [Related]
16. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L; Lonardi S; Masi G; Loupakis F; Bergamo F; Salvatore L; Cremolini C; Schirripa M; Vivaldi C; Aprile G; Zaniboni A; Bracarda S; Fontanini G; Sensi E; Lupi C; Morvillo M; Zagonel V; Falcone A
Ann Oncol; 2013 Aug; 24(8):2062-7. PubMed ID: 23666916
[TBL] [Abstract] [Full Text] [Related]
17. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.
Nikkels AF; Piérard-Franchimont C; Nikkels-Tassoudji N; Bourguignon R; Piérard GE
Acta Clin Belg; 2005; 60(5):227-34. PubMed ID: 16398319
[TBL] [Abstract] [Full Text] [Related]
18. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma?
Jansen EP; Keus RB; Hilgers FJ; Haas RL; Tan IB; Bartelink H
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):27-35. PubMed ID: 10924968
[TBL] [Abstract] [Full Text] [Related]
19. The influence of fraction size in radiotherapy on the late normal tissue reaction--II: Comparison of the effects of daily and twice-a-week fractionation on human skin.
Turesson I; Notter G
Int J Radiat Oncol Biol Phys; 1984 May; 10(5):599-606. PubMed ID: 6429092
[TBL] [Abstract] [Full Text] [Related]
